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ABSTRACT
Objective: Contrast methods to assess the health effects of a
treatment rate change when treatment beneﬁts are heteroge-
neous across patients. Antibiotic prescribing for children with
otitis media (OM) in Iowa Medicaid is the empirical example.
Methods: Instrumental variable (IV) and linear probability
model (LPM) are used to estimate the effect of antibiotic
treatments on cure probabilities for children with OM in
Iowa Medicaid. Local area physician supply per capita is the
instrument in the IV models. Estimates are contrasted in
terms of their ability to make inferences for patients whose
treatment choices may be affected by a change in population
treatment rates.
Results: The instrument was positively related to the prob-
ability of being prescribed an antibiotic. LPM estimates
showed a positive effect of antibiotics on OM patient cure
probability while IV estimates showed no relationship
between antibiotics and patient cure probability.
Conclusions: Linear probability model estimation yields the
average effects of the treatment on patients that were
treated. IV estimation yields the average effects for patients
whose treatment choices were affected by the instrument.
As antibiotic treatment effects are heterogeneous across
OM patients, our estimates from these approaches are
aligned with clinical evidence and theory. The average esti-
mate for treated patients (higher severity) from the LPM
model is greater than estimates for patients whose treat-
ment choices are affected by the instrument (lower severity)
from the IV models. Based on our IV estimates it appears
that lowering antibiotic use in OM patients in Iowa
Medicaid did not result in lost cures.
Keywords: antibiotics, instrumental variables, otitis media,
treatment effectiveness.
Introduction
Otitis media (OM), middle ear infection, is the leading
disease related to antibiotic use in the United States
and antibiotics were prescribed for nearly 80% of OM
patients between 1998 and 2000 in the USA [1,2]. Two
thirds of antibiotic prescriptions for children less than
three in Iowa in 1995 were related to OM [3]. It is
thought that antibiotics are routinely overprescribed
for OM which promotes the spread of antibiotic resis-
tance [1,4–6]. In 1995, the Center for Disease Control
began a national campaign to discourage antibiotic
overuse in general by educating ofﬁce-based providers
which led to a 32% reduction in antibiotic prescribing
rates [7,8]. In 1999 a behavioral intervention from the
Iowa Department of Public Health (IDPH) led to a
20% reduction in the antibiotic prescribing rate in the
Iowa Medicaid population [9]. Several studies have
been used to justify reducing antibiotic prescribing
rates [1,4–6,10]. Nevertheless, these studies focused
mainly on the beneﬁts of reduced antibiotic resistance
and either ignored or assumed away any cures lost by
patients not receiving antibiotics at lower treatment
rates. It is not clear whether this assumption is valid
for the set of patients whose treatment choices are
affected when overall treatment rates change.
We refer to the set of patients whose treatment
choices are affected when treatment rates change as the
patients on the extensive margin, and for OM patients
on the extensive margin it is not clear whether the
assumption of no lost cures is valid. Randomized con-
trolled trials (RCT) suggest positive beneﬁts from
antibiotics for children with OM. Meta-analyses by
Rosenfeld and colleagues [11] and Takata and col-
leagues [12] showed antibiotic beneﬁts of 13.7% and
12% relative to watchful-waiting, respectively. A sub-
sequent evaluation of the controlled trials used in these
studies suggested that they included patients with
“mild to moderate” OM symptom severity and that
the average beneﬁt of antibiotics for more severe OM
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patients was probably higher [13]. A later study by
McCormick and colleagues using nonsevere cases of
children diagnosed with acute OM showed 16% fewer
treatment failures for children with antibiotics treat-
ment relative to children with watchful waiting [14].
This evidence suggests that it may be inappropriate to
assume that the OM patients on the extensive margin
will not beneﬁt from antibiotics. On the other hand, it
may also be inappropriate to assume that the RCT
evidence can be generalized to these patients. Other
studies have shown substantial heterogeneity in the
beneﬁt of antibiotics across children with OM (Rovers
et al. [15]) and that the beneﬁt of antibiotics decreases
with decreased OM severity (Kaleida [16]). Based on
these results, the American Academy of Pediatrics and
the American Academy of Family Physicians suggest
higher antibiotic prescribing rates for more severe OM
patients [17]. Given this evidence of heterogeneity, it
may also be inappropriate to assume that RCT esti-
mates can be generalized directly to the patients on the
extensive margin.
Are there alternative methods to ﬁnd estimates for
patients on the extensive margin when treatment ben-
eﬁts are heterogeneous across patients? Because the
extensive margin is deﬁned by the treatment choices
made by patients and their providers in practice, the
potential exists for researchers to exploit existing
treatment variation within observational health-care
databases to obtain these estimates. It is well-known,
though, that observational health-care databases
provide inadequate measures of many confounding
variables which leads to inferential difﬁculties when
estimating treatment effects [18–21]. In spite of these
difﬁculties, under certain circumstances, estimates
from observational health-care databases may have
advantages over RCT results in making inferences for
patients on the extensive margin. The goal of this study
is to contrast methods to estimate the treatment ben-
eﬁts for patients on the extensive margin when the
treatment beneﬁt is thought to be heterogeneous across
a patient population. Speciﬁcally, we contrast the
ability of RTC evidence, standard regression methods,
and instrumental variable (IV) methods to estimate the
treatment effects for OM patients on the extensive
margin in the Iowa Medicaid Program. In the remain-
der of the introduction we provide a theoretical justi-
ﬁcation for assessing the treatment effects for patients
on the extensive margin when treatment effects are
thought to be heterogeneous. This is followed by a
discussion of the properties of standard regression esti-
mates and IV estimates of the effect of antibiotic treat-
ment for OM patients using data from observational
health-care databases. We argue that standard regres-
sion methods yield estimates of the average treatment
effect for the treated patients in a population and in
this clinical scenario these estimates will be biased low
because of treatment selection related to unmeasured
severity. Nevertheless, even with this bias, estimates
from standard regression methods may be biased high
for OM patients on the extensive margin as the
patients on the extensive margin will have average
severity levels lower than treated OM patients. IV
methods yield estimates for the set of patients whose
treatment choices are affected by an “instrument.”
These patients may be similar to patients on the exten-
sive margin as instruments will tend to affect the treat-
ment choices for the subset of patients for whom the
best treatment is least certain (patients least like those
in the RCT samples).
Theoretical Model of Treatment Effects on the
Extensive Margin
The assumption that reduced antibiotic treatment rates
for OM patients will not result in lost cures is incon-
sistent with the notion that patients and providers treat
OM with antibiotics with the expectation that antibi-
otics will help the patient. These ideas are consistent
only if patients and providers had inﬂated expectations
of the effectiveness of antibiotics in the treatment of
OM. These concepts are illustrated in Figure 1. The
horizontal (X) axis represents the antibiotic treatment
rate for patients diagnosed with OM within a popula-
tion. The vertical (Y) axis is measured in monetary
terms and reﬂects both the expected value of antibiotic
treatment beneﬁt relative to watchful waiting and the
cost of antibiotics. CS is the total cost of an additional
antibiotic prescription to society which includes both
the direct cost of the antibiotic to the payers (patient
plus third party) and the cost to society associated with
antimicrobial resistance. We assume that CS increases
as resistance cost increases with the treatment rate.
Based on the variation in antibiotic beneﬁt observed in
the clinical evidence we also assume that the expected
value of an antibiotic prescription varies across OM
patients in the population with 1) the expected anti-
biotic effectiveness relative to watchful waiting (i.e.,
expected increase in cure probability); and 2) how
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Figure 1 Optimal antibiotic treatment rates given assumed demand and
societal treatment cost. OM, otitis media.
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much patients value the beneﬁt (value of a cure). We
assume that patients’ treatment effectiveness expecta-
tions are formed in concert with recommendations
from their physicians.
If we vary the out-of-pocket antibiotic price and
ﬁnd the percentage of OM patients willing to purchase
antibiotics at each price we could trace out a derived
demand curve for antibiotics relative to watchful
waiting. At any given price, only OM patients with
expected antibiotic valuations greater then the price
will demand antibiotics. As the price falls additional
OM patients with lower expected antibiotic valuations
will demand antibiotics yielding a downward sloping
derived demand curve for antibiotic prescriptions
related to OM. If the value associated with a cure is
fairly consistent across patients, the shape of the
derived antibiotic demand curve will be determined by
the distribution of the expected effectiveness of antibi-
otics relative to watchful waiting across the OM popu-
lation. Assume that the solid curve in Figure 1 is the
derived antibiotic demand curve for an OM popula-
tion that reﬂects the distribution of each decision-
maker’s (patient in concert with provider) expected
effectiveness of antibiotics relative to watchful waiting
across the population. If the population is fully insured
and antibiotics are costless to patients, the observed
antibiotic treatment rate would be R1. At R1 all
patients having a positive expected value for antibiot-
ics relative to watchful waiting would receive treat-
ment. Nevertheless, because antibiotic prescribing has
negative externalities to society through the spread of
antibiotic resistance, at R1 the beneﬁt of antibiotics is
less than the cost of antibiotics to society and the
antibiotic treatment rate should be reduced optimally
to R2 where the marginal beneﬁt of antibiotic treat-
ment equals its marginal societal cost.
It should be noted, though, that reducing the antibi-
otic treatment rate from R1 to R2 would withhold
antibiotics from patients with a positive expected anti-
biotic valuation (patients whose derived demands are
represented between points A and B on the solid derived
demand curve), and these lost valuations need to be
included in an assessment of the rate change. The
assumption that no treatment beneﬁts would be lost if
treatment rates were reduced from R1 to R2 must
assume that before the rate reduction antibiotic pre-
scriptions were given to OM patients in a range below
R1 thatwere ultimately of little or no value to patients as
would be the case if the dotted demand curve in Figure 1
represented the true antibiotic effectiveness across the
OM population. A difference between the true value
and the expected value of a treatment may occur if
patients and providers have inﬂated expectations of the
effectiveness of a treatment. If the dotted derived
demand curve reﬂects the true treatment value of anti-
biotics to patients, it would be optimal to reduce the
antibiotic treatment rate to R3. Nevertheless, if patient/
provider expectations reﬂect the true value of the treat-
ment (i.e., true effectiveness is represented by the solid
derived demand curve) and policymakers incorrectly
assume the dotted derived demand curve reﬂects true
effectiveness and reduce the rate to R3, children with
OMthatwould have valued antibiotics at a level greater
than its cost would not receive treatment and welfare
would be reduced by the area BCD. Therefore, policy-
makers should attempt to get a clear understanding of
the effects of treatment on the patients potentially
affected before the implementation of a policy to lower
antibiotic treatment rates. The question then is which
treatment effect estimate best applies to these patients.
Estimation Approaches and Inferences
A confounding variable is related to both treatment
choice and outcome and the inability to accurately
control for confounding variables can lead to inappro-
priate inferences [18–21]. In this case, antibiotics
provide more beneﬁt for patients with more severe
symptoms and OM patients with more severe symp-
toms are less likely to be cured regardless of treatment
[13,15,16,22,23]. Generally, though, the data within
observational databases are insufﬁcient to describe the
OM severity information available to patients and
physicians (e.g., fever) when treatment decisions are
made. Below we use a simple modeling structure to
describe the relationship between unmeasured severity
and the estimation approaches used in this analysis
and contrast the ability of these approaches to provide
information for the patients on the extensive margin.
Based on the relationship between symptom severity
and antibiotic efﬁcacy for OM patients from the clini-
cal evidence, we model the underlying outcome rela-
tionship as:
Y b b L T b L e= + ⋅( )⋅ + ⋅ +0 1 2 , (1)
where Y equals 1 if cured, 0 otherwise; T equals 1 if the
patient received antibiotics, 0 watchful waiting; L
equals unmeasured severity such that L increases with
symptom severity; e is the error term; b2 equals the
direct effect of L on Y; and (b1·L) = effect of antibiotics
(T) on cure (Y) that depends on severity (L). Based on
the clinical evidence for OM and antibiotics we expect
b2 < 0 (probability of a cure decreases with severity
regardless of treatment) and b1 > 0 (the effect of
antibiotics on outcome is positive and increases with
severity).
For illustrative purposes, initially suppose that
treatments are assigned randomly to a sample of
patients from a population of children with OM so
that T and L are not related in the sample and the
following model is estimated:
Y a a T u= + ⋅ +0 1 , (2)
where u contains the previous error term and variation
in treatment effectiveness associated with L. Under
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random treatment assignment the expected value of
the standard regression estimator of a1 – â1 equals:
E E ,aˆ b L T1 1 1[ ] = ⋅ =[ ] (3)
where E[L|T = 1] equals the average severity level of
the patients in the sample that were treated. This result
follows from the theoretical work of Heckman and
colleagues [24,25] and as such yields the average treat-
ment effect for the treated patients in the sample.
Therefore, even with random treatment assignment
when treatment effects are heterogeneous it is prob-
lematic to generalize estimates from samples to
patients with severity levels in the population that
differ from the average severity of the sample.
If treatment is not assigned randomly and treatment
choice is affected by unmeasured (to the researcher)
patient severity one needs to specify a treatment choice
model to evaluate this effect:
T c c L c W v= + ⋅ + ⋅ +0 1 2 , (4)
where T and L are deﬁned as above; W represents
factors other than severity that affect treatment choice;
v is the error term; and c1 equals the effect of severity
on treatment choice. One would expect the signs asso-
ciated with b1 from equation 1 and c1 to be the same.
For example, in this case if the effectiveness of T is
thought to increase with L (b1 > 0), the patients with
higher severity will more likely be treated (c1 > 0).
Under this treatment choice rule, standard regression
estimation of the model in equation 2 for a sample of
OM patients from the population would yield an esti-
mate of a1 with the following expected value:
E Eˆ .a b L T c b1 1 1 21[ ] = ⋅ =[ ] + ⋅ (5)
Again, after the work of Heckman and colleagues
[24,25], this estimate is an average estimate of the
effect of antibiotics for the treated OM patients in the
sample but this time it will be biased low as c1 > 0 and
b2 < 0. Simply put, the estimated effect of the treatment
on the treated in the sample is biased low because
treated patients have higher severity levels than non-
treated patients leading to fewer cures regardless of
treatment. Relative to Figure 1 this estimate of â1 can
be interpreted as a lower-bound estimate of the
average treatment effect of antibiotics for the treated
patients from the origin to R1.
In contrast, the IV approach estimates a1 by exploit-
ing the treatment variation stemming from measured
factors within “W” in equation 4 that are assumed
uncorrelated with unmeasured confounders such as
severity and affect the probability of a patient being
cured only through their effects on treatment choice.
Deﬁne “Z” as the measured factors within “W”
assumed to have this characteristic and “X” as the
factors within “W” that do not. Given this informa-
tion, equations 1 and 4 can be rewritten in terms of
measured variables:
T c c X c Z u= + ⋅ + ⋅ +0 2 2 , (6)
Y a a T a X r= + + ⋅ +0 1 2 , (7)
where u and r contain the original error terms plus
terms related to severity. In the ﬁrst stage of IV analysis
equation 6 is estimated. A Chow F-test [26] of the
estimated parameter vector c3 can be used to assess
whether the instruments Z describe a signiﬁcant
portion of the variation in antibiotic prescribing. In the
second stage, equation 7 is estimated after replacing
the actual treatment variable T with the predicted
treatment variable from equation 6—Tˆ. Because X is
speciﬁed in both equations, the only variation in Tˆ that
is used to estimate a1 in equation 2 is the T variation
associated with Z. Given the assumed properties of Z,
variation in Z essentially provides a natural experi-
ment using the variation in T related to Z [27]. The IV
estimate of a1—â1IV—provides a consistent estimate of
the average change in the cure probability from treat-
ment relative to watchful waiting that can only be
strictly generalized to the patients whose treatment
choices were affected by the instrument. Imbens and
Angrist interpreted this as a local average treatment
effect [28] which can be written using the model here
as:
E E ,IVaˆ b L T Z1 1[ ] = ⋅ ( )[ ] (8)
where E[L|T(Z)] equals the expected unmeasured
severity level for the patients in the sample whose
treatment choices were affected by the instrument.
Note that if the antibiotic treatment effect is heteroge-
neous across OM patients, the average estimates of the
treatment on the treated in equation 3 and the IV
estimates in equation 8 will differ. If providers are
more apt to prescribe antibiotics to patients with more
severe symptoms one would expect the average sever-
ity level of treated patients (E[L|T = 1]) in practice to
be greater than the average severity level of patients
whose treatments were affected by instruments
(E[L|T(Z)]). In addition, because Z affects only the
treatment choices of a subset of patients, the ability to
generalize IV estimates to patients beyond this subset is
limited. Nevertheless, if treatment effects are heteroge-
neous across patients, IV estimates may be better-
suited than RCT estimates to evaluate treatment
beneﬁts for patients on the extensive margin. In previ-
ous IV research in health care, the set of patients whose
treatment choices were determined by instruments
have been referred to as “marginal patients” [29,30].
While the marginal patients for a given instrument and
the patients on the extensive margin for a given behav-
ioral intervention may not be identical, it has been
argued that both patient subsets are drawn from a
larger set of patients for whom the best treatment
choice is least certain [29–33]. The logic is that it is not
likely that either the patients whose treatment choices
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are affected by an instrument or the set of patients
whose treatments change when treatment rates change
will be from the set of patients for whom the best
treatment is certain (patients most like those in the
RCT samples). Therefore, since patients from both
subsets are drawn from the same underlying popula-
tion, estimated treatment effects for marginal patients
may be better suited to provide information about




In this study we used the physician supply per capita in
the area around the patient’s residence as an instru-
ment. We theorized that local area physician supply
affects the antibiotic treatment choices of individual
OM patients. Parents of children with OM symptoms
typically visit physicians with the belief that antibiotic
treatment is more effective than watchful-waiting [34],
and often expect or request to be treated with anti-
biotics [35,36]. If patients are not prescribed antibiot-
ics according to parent expectations, they may be
dissatisﬁed and choose another doctor if other physi-
cians are available [37]. Therefore, physicians practic-
ing in areas with higher physician supply per capita
may have greater incentive to respond to parent wishes
and prescribe antibiotics to reduce the risk of losing
patients to other physicians. In addition, we assumed
that physician supply per capita is not systematically
related to unmeasured confounding variables such as
average patient OM severity levels. The plausibility of
this assumption rests on the notion that patients
choose where to live without knowledge of the severity
of future acute conditions that may affect their family.
It is possible, though, that OM patients living in areas
with more physicians per capita may be healthier in
general as a result of easier access to health care than
OM patients living in areas with fewer physicians. If
OM patients in areas with higher physician supply are
generally healthier, IV estimates of the effect of antibi-
otics using the variation in antibiotic treatments
related to local area physician supply will be biased
high and will represent an upper-bound estimate. We
interpret our IV estimates in light of this possibility.
In estimation we employed a nonparametric two-
stage least squares (IV-2SLS) variant of IV estimation
with a minimum of parametric and distributional
assumptions that has been used in previous IV research
in health care [30–33,38,39] to estimate â1IV in equa-
tion 7. Despite the speciﬁcation of binary dependent
variables in equations 6 and 7, nonparametric IV-2SLS
provides consistent estimates regardless of the under-
lying error distributions, whereas alternative two-stage
estimators that rely on distributional assumptions are
inconsistent if the assumptions are incorrect [40]. All
independent variables in both models were speciﬁed
using binary variables including the instrument. Our
choice of binary instead of continuous instruments is
based on the extensive methodological development
underlying the binary approach both in terms of sta-
tistical properties and inferences [41,42], and the
direct interpretation of estimates as the local average
effect for those patients whose treatment would have
changed if they had changed groups [43]. The binary
variables for the instrument grouped patients with
similar instrument values and were speciﬁed to coor-
dinate with percentiles of area physician supply per
capita across the sample. To assess whether our
IV-2SLS results are robust to the instrument speciﬁca-
tion we estimated the models in which the instrument
grouped patients into 20 categories (5th percentile), 10
categories (10th percentile), ﬁve categories (20th per-
centile), four categories (25th percentile), and two cat-
egories (50th percentile). In addition, we contrasted
the IV-2SLS estimates to standard regression estimate
of â1 using a linear probability model (LPM) estimated
with ordinary least squares. LPM estimation is used
because its estimates are more directly comparable
with IV-2SLS estimates [30] and we interpret the LPM
estimates in light of the relationship in equation 5.
IV-2SLS models were estimated using the IVREG pro-
cedure and the LPM models were estimated using the
REGRESS procedure both in STATA. All models esti-
mated using the ROBUST option in STATA that yields
standard error estimates robust to the error structure
across observations.
The extent that inferences can be made from
IV-2SLS estimates is based on the assumption that
the level of physician supply per capita around each
patient affects treatment choice and is unrelated to the
distributions of unmeasured confounders across geo-
graphic areas. We provide Chow F-statistics associated
with the instruments for each IV-2SLS speciﬁcation of
the “ﬁrst-stage” antibiotics choice model and provide
the entire ﬁrst-stage model results for the speciﬁcation
in which patients are grouped based on the quartiles of
the instrument. The assumption of whether our instru-
ment is unrelated to unmeasured confounders cannot
be validated with existing data but it can be scrutinized
to some extent. IV-2SLS models in which the instru-
ment is speciﬁed with more than two groups are said to
be overidentiﬁed and a Hausman test statistic [44] can
be estimated to test the null hypothesis that the exclu-
sion of the instrument from the equation 7 was appro-
priate (a test of whether the patient groups speciﬁed
using the instrument simultaneously had no direct on
cure or no indirect effect on cure through an unmea-
sured confounding variable). A large value of the
Hausman statistic rejects the null hypothesis. As is
performed in RCT, we also assessed whether measured
confounders were balanced across patients grouped by
high and low area physician supply per capita. Finding
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unbalanced measured confounders across patients
grouped by our instrument makes the inferences from
IV-2SLS estimates conditional on the assumption that
differences in measured confounders are not symptom-
atic of differences in unmeasured confounders and it
reinforces the need to control for measured confound-
ers directly in IV-2SLS analysis (X in eqns 6,7).
Data and Variable Deﬁnitions
Data were obtained from the Iowa Medicaid data ﬁles
from 1996 to 2002, Iowa Physician Inventory Files
(IPI) from 1996 to 2002, and the Bureau of the Census’
1990 and 2000 Summary Tape File by Zip Code Area
(STF3B). The Iowa Medicaid ﬁles included enrollment,
medical (physician) claims, institutional (hospital)
claims, pharmacy claims, and provider ﬁles. Medicaid
data provided information on patient demographics,
OM diagnoses, comorbidities, providing physician
specialty, zip code at diagnosis, and antibiotic treat-
ment for each patient. The IPI data provided physician
counts by practice location for each zip code in Iowa
from 1996 through 2002. The Census data were used
to obtain zip code-level population counts.
OM episodes were developed for each Iowa Med-
icaid medical claim from August 30, 1996 through
August 29, 2002 with an OM diagnosis and the
patient associated with the claim had no medical
claims with an OM diagnosis in the previous
6 months. The dates on the medical claims that satis-
ﬁed these criteria were deﬁned as the index dates for
OM episodes. OM claims were identiﬁed using the
ICD-9-CM codes associated with OM including non-
suppurative OM (381.0X, 381.1X, 381.2X, 381.3,
and 381.4) and suppurative and unspeciﬁed OM
(382.0X, 382.1, 382.2, 382.3, 382.4, and 382.9). We
excluded episodes for patients who were 13 years or
older at the time of the OM episode and were not
continuously eligible with non-HMO Medicaid cover-
age for 6 months before to 1 month after the index
OM claim. After the methods of previous observa-
tional studies in OM [45], we also excluded episodes
for patients who were hospitalized with diagnoses of
sepsis, bronchiolitis, croup, meningitis, sinusitis, pneu-
monia, or mastoiditis in the 24 days before the index
date or had ambulatory visits with secondary diag-
noses of mastoiditis, hearing loss, cholesteatoma, or
perforation in the 24 days before the index date. Epi-
sodes were also excluded if the specialty of the pro-
vider on the index medical claim was missing or if the
patient’s residence zip code was missing from the
enrollment ﬁles. Finally, for children with more than
one OM episode we included only their ﬁrst episode in
the analysis data set.
For each OM episode, Medicaid claims and enroll-
ment data were used to create binary variables deﬁning
treatment choice (antibiotics or watchful-waiting) and
outcome (cured or not-cured). A patient was desig-
nated as treated with antibiotics if the patient had a
pharmacy claim for antibiotics within 2 days of the
date of the index medical claim. If no prescription was
observed during this period, the patient was designated
as watchful-waiting. We designated a patient as cured
if the patient had no antibiotic prescriptions, addi-
tional physician visits, or hospitalizations for OM
between 3 and 14 days of the index OM. This measure
probably overstates the cure rate in our sample as
many children not cured do not return for further
treatment. When comparing the treated and non-
treated groups in this study we are assuming that the
rate of unreported treatment failures is consistent
across groups.
We measured several confounding variables (X in
eqns 6,7) including whether the index episode was
diagnosed as acute OM (AOM)—ICD-9 codes 381.0X
or 382.0X as a measure of OM severity, comorbidities
(upper respiratory tract infection, tonsillitis, pneu-
monia, and bronchitis), age (0–1 year, 2–3 years,
4–6 years, or 7–12 years), sex, race (white, black, or
other), diagnosis season (warm or cold), year of diag-
nosis, and provider specialty (family practice, general
practice, pediatrics, otolaryngologist, and other spe-
cialty). For each patient we calculated the number of
physicians per capita in the 10-mile radius around
patient zip codes in the year of the OM episode. To do
this we ﬁrst calculated the number of physicians prac-
ticing in each zip code in each year using the IPI
database and estimated the population of each zip
code in each year after extrapolating 1990–2000 zip
code level population trends across years. Next, for
each zip code containing a patient in our sample we
found all the zip codes within 10 miles. Distances were
calculated using the longitudes and latitudes of zip
code centroids. We then summed the number of prac-
ticing physicians and populations across the zip codes
within 10 miles to obtain the numerator and denomi-
nator of our instrument.
Results
There were 36,585 patients that met the selection cri-
teria for the index OM between 3 years pre- and post-
IDPH educational intervention periods. Among the
study population, 28,298 patients (77.35%) were ini-
tially treated with an antibiotic prescription within
2 days of the index diagnosis, and the rest (22.65%)
received watchful-waiting. Table 1 compares the mean
values of measured confounders across patients using
two different patient grouping methods. Columns 3
and 4 compare patients based on treatment choice.
Columns 4 and 5 compare patients by physician
supply per capita in the area around where they live by
dividing patients into “high” and “low” groups based
on the median of physician supply per capita across the
sample. We tested the difference in means of each
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measured confounder across groups (antibiotics vs.
watchful waiting and low vs. high physicians per
capita) but because of our large sample size many
small differences in the measured characteristics across
groups are statistically signiﬁcant. As a result, we
focused on overall differences between patient groups
and whether these differences changed with the
method used to group patients.
Relative to watchful waiting patients, patients
treated with antibiotics appeared more severe as their
conditions were more often designated as acute
(AOM) and they had more comorbidities. Despite the
apparent higher average severity levels for treated
patients, though, they had a higher cure rate than
watchful waiting patients (82.34% vs. 74.44%). In
addition, larger percentages of patients receiving anti-
biotics were diagnosed in the early years of the obser-
vation period and were treated by family practice
physicians. In contrast, grouping patients by the phy-
sician supply per capita in the area around their resi-
dence provided more balance in measured severity and
comorbidities. The percentage of patients with an
AOM diagnosis was virtually identical across patients
grouped by physician supply per capita. The differ-
ences that remain across patients grouped by physician
supply per capita appear related to geographic distri-
butions of race and physician specialties across
Iowa. Areas with lower physician supply per capita
tend to be in rural areas that have lower minority
representation, more family practitioners, and fewer
pediatricians.
Table 2 contains the ﬁrst-stage antibiotic choice
regression estimates with the instrument speciﬁed
using four patient groups based on the quartiles of the
instrument. After controlling for other covariates,
patients living in an area with higher physician supply
per capita had a greater chance of being prescribed an
antibiotic than patients living in an area with lower
physician supply per capita (P < 0.0001). In addition,
younger patients (P < 0.0001), white patients relative
to African American patients and patients of other
races (P < 0.0001), patients with AOM (P < 0.0001),
Table 1 Comparison of patient characteristics across OM patients in Iowa grouped by treatment and instrumental variable,














0–1 40.27 40.48 39.54 39.77* 40.76
2–3 18.58 18.64 18.37 18.34 18.82
4–6 20.44 20.20* 21.25 20.72 20.16
7–12 20.72 20.68 20.84 21.17* 20.26
Sex (%)
Male 51.07 50.78* 52.05 51.12 51.01
Race (%)
White 76.55 76.91* 75.35 82.20* 70.91
Black 5.89 5.86 5.97 1.63* 10.14
Other 17.56 17.23* 18.68 16.17* 18.95
AOM diagnosis (%) 28.26 30.06* 22.09 28.12 28.39
Diagnosis with URTI (%) 26.55 17.79* 12.13 14.99* 18.02
Diagnosis with tonsillitis (%) 0.47 0.21* 1.35 0.50 0.44
Diagnosis with pneumonia (%) 0.02 0.02 0.02 0.00* 0.05
Diagnosis with bronchitis (%) 2.95 3.31* 1.74 3.22* 2.69
Cold season of diagnosis (%) 65.08 66.56* 60.00 65.48* 64.67
Year of diagnosis (%)
1996 9.66 10.06* 8.30 10.66* 8.67
1997 23.24 23.53* 22.24 23.05 23.42
1998 15.85 16.09* 15.04 16.06 15.64
1999 13.69 13.18* 15.45 13.56 13.83
2000 12.57 12.27* 13.59 12.28 12.86
2001 15.51 15.38 15.98 15.07* 15.96
2002 9.47 9.49 9.41 9.33 9.61
Provider specialty (%)
General practice 36.20 35.12* 39.88 37.07* 35.33
Family practice 31.16 33.34* 23.71 39.02* 23.30
Pediatrics 15.93 16.44* 14.18 8.65* 23.21
Otolaryngologist 3.09 0.88* 10.64 3.04 3.14
Other specialty 13.62 14.22* 11.58 12.22* 15.02
Antibiotic treatment (%)
Antibiotics 77.35 100 0 76.58* 78.12
Cure outcome (%) 80.55 82.34* 74.44 80.75 80.65
Number of patients in group 36,585 28,298 8,287 18,287 18,298
*Mean difference in characteristic between comparison groups (antibiotics vs. watchful waiting and lower vs. higher physician supply) is statistically different from zero (P < 0.05).
†Patient in “low” group if less than the median of physician supply per capita in the 10-radius around the patient’s residence in the year of diagnosis of OM.
AOM, acute otitis media; URTI, upper respiratory tract infection.
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patients with upper respiratory tract infections
(P < 0.0001), patients with bronchitis (P < 0.0001),
patients diagnosed in cold months (P < 0.0001), and
patients diagnosed by a family practitioner relative to
other specialties (P < 0.0001) had a higher probability
of receiving an antibiotic prescription. OM patients
diagnosed in the years after the IDPH intervention
generally had lower antibiotic treatment rates.
Table 3 contains IV-2SLS and LPM estimates of the
effect of antibiotic treatment relative to watchful-
waiting on probability of cure for OM patients. For
each IV-2SLS speciﬁcation the third column lists the
range in unadjusted antibiotic treatment rates found
across the patients grouped by the binary variables
representing area physician specialty per capita in their
area. The F-statistics in the fourth column show
whether the binary variables associated with the instru-
ment described a statistically signiﬁcant portion of the
variation in antibiotic prescribing for OM. The ﬁfth
column contains the overidentiﬁcation test statistics for
the IV-2SLS models deﬁned with more than two patient
groups. The null hypothesis that the instrument was
unrelated to outcomes was rejected only in the speciﬁ-
cation in which the instrument was speciﬁed using 20
patient groups. The sixth column contains the esti-
mated effect on the probability of cure from the use of
antibiotics for both the LPM and IV-2SLS models.
Using LPM, after controlling for measured confound-
ers, patients that received antibiotics had a cure prob-
ability 7.3% higher than watchful waiting patients and
this was statistically signiﬁcant at the .05 level. The
IV-2SLS estimates of the antibiotic treatment effect
varied substantially across the speciﬁcations and no
statistically signiﬁcant positive effects of antibiotic
treatment relative to watchful waiting were found.
Conclusions
The goal of this research was to contrast methods to
assess treatment beneﬁts on the extensive margin when
the beneﬁts of treatment are thought to be heteroge-
neous across a patient population. We use antibiotic
Table 2 First-stage ordinary least squares estimates of factors with effecting antibiotic treatment choice for OM patients in Iowa
medicaid (N = 36,585)
Variables Estimate Standard error P-value F-statistic (P-value)
Intercept 0.792* 0.010 <0.0001
Physician supply
2nd quartile vs. 1st quartile 0.009 0.006 0.129 11.98* (<0.0001)
3rd quartile vs. 1st quartile 0.035 0.006 <0.0001
4th quartile vs. 1st quartile 0.020 0.006 0.001
Age group
0–1 vs. 7–12 -0.015* 0.006 0.011 2.51 (0.057)
2–3 vs. 7–12 -0.005 0.007 0.489
4–6 vs. 7–12 -0.011 0.007 0.106
Sex
Male vs. female -0.004 0.004 0.295 1.10 (0.294)
Race
Black vs. white -0.021* 0.009 0.025 8.10* (0.0003)
Other vs. white -0.020* 0.006 0.003
Diagnosis with AOM
Yes vs. No 0.049* 0.005 <0.0001 46.16* (<0.0001)
Diagnosis with URTI
Yes vs. No 0.055* 0.006 <0.0001
Diagnosis with tonsillitis
Yes vs. No -0.049 0.032 0.125
Diagnosis with pneumonia
Yes vs. No -0.037 0.134 0.782
Diagnosis with bronchitis
Yes vs. No 0.074* 0.012 <0.0001
Diagnosis season
Cold season vs. warm season 0.039* 0.004 <0.0001 75.63* (<0.0001)
Year of diagnosis
1997 vs. 1996 -0.005 0.008 0.529 4.43* (<0.0001)
1998 vs. 1996 0.000 0.009 0.966
1999 vs. 1996 -0.037* 0.009 <0.0001
2000 vs. 1996 -0.032* 0.009 0.0007
2001 vs. 1996 -0.023* 0.009 0.010
2002 vs. 1996 -0.014 0.010 0.149
Provider specialty
General practice vs. family practice -0.071* 0.005 <0.0001 517.64* (<0.0001)
Pediatrics vs. family practice -0.039* 0.007 <0.0001
Otolaryngologist vs. family practice -0.588* 0.013 <0.0001
Other specialty vs. family practice -0.023* 0.007 0.015
*Statistically signiﬁcant at P < 0.05.
AOM, acute otitis media; URTI, upper respiratory tract infection.
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use for OM patients in the Iowa Medicaid Program as
our empirical example. Researchers claim that antibi-
otics are routinely overprescribed for OM and antibi-
otic prescribing rates for OM need to be lowered
[1,4–6]. Nevertheless, an assessment of a policy to
lower antibiotic treatment rates for OM patients needs
to account for the potential effects on the patients that
would not receive treatment as a result of the lower
rates—the patients on the extensive margin. Clinical
studies suggest that the effectiveness of antibiotics for
patients with OM increases with the severity of the
condition and, as a result, it is unclear which if any
clinical result can be appropriately applied to OM
patients on the extensive margin.
The treatment choices for patients on the extensive
margin can be found in observational databases, but
these databases often contain insufﬁcient information
to measure the range of variables needed to avoid
confounding problems using standard regression
methods. In the case of antibiotics and OM, based on
clinical study results we theorized that patients with
more severe cases have a higher probability of being
treated and that many of the indications of OM sever-
ity (e.g., fever) are unmeasured in observational data-
bases. In this scenario we showed that standard
regression approaches using observational data will
yield average estimates for the treated OM patients in
the population that are biased low. Nevertheless, even
if severity was fully accounted for, if antibiotic beneﬁts
vary across OM patients, an estimate of the effect of
antibiotics for the average treated OM patient may be
inappropriate for the patients on the extensive margin.
We then used IV analysis. In IV analysis “instru-
ments” are measured variables that affect treatment
choice and are assumed to have no direct effect on
outcomes and are unrelated to unmeasured confound-
ers. IV methods yield estimates for patients whose
treatment choices vary with the instruments. We
argued that in clinical scenarios like antibiotics for
OM in which the beneﬁts from treatment vary, patients
on the extensive margin and patients whose treatment
choices are affected by instruments are drawn from a
larger set of patients for whom the best treatment
choice is least certain [29–33]. Therefore, IV estimates
may be better suited to provide information about
patients on the extensive margin than estimates from
standard regression models or even existing RCT evi-
dence. We used the number of physicians per capita in
the area around each OM patient as the instrument in
our analysis. We found that OM patients living in
areas with higher physician supply per capita had a
higher chance of being prescribed an antibiotic than
patients in areas with lower physician supply per
capita (P < 0.001). In contrast to grouping OM
patients by treatment choice, we found in Table 1 that
grouping patients by local area physician supply per
capita provided a better balance of measured covari-
ates related to OM severity and comorbidities.
Using a LPM we found that OM patients treated
with antibiotics had a 7.3% greater chance of a cure
than patients receiving watchful waiting (P < 0.05). If
physicians followed prescribing recommendations [17]
and patients with more severe OM had higher antibi-
otic treatment rates than patients with less severe OM,
Table 3 Two-stage least squares (IV-2SLS) and standard risk-adjustment linear probability model (LPM) estimates of the effectiveness























LPM§§ N/A N/A N/A 0.073*
(<0.0001)




























*Statistically different at P < 0.05.
†Chow test of the effects of the binary variables speciﬁed for the instrument in equation 6.
‡F-test from two-stage least square methods using equations 6 and 7.
§Two categories grouped by 50 percentile of physician supply per capita.
¶Four categories grouped by 25 percentile of physician supply per capita.
**Five categories grouped by 20 percentile of physician supply per capita.
††Ten categories grouped by 10 percentile of physician supply per capita.
‡‡Twenty categories grouped by 5 percentile of physician supply per capita.
§§LPM—standard risk adjustment linear probability model. IV-2SLS – the stage-least squares variant of instrumental variable model.Also speciﬁed in models were binary variables
for physician supply per capita (higher or lower), age groups (<2, 2–4, 4–6, 7–13), sex (male or female), race groups (white, black, other),AOM diagnosis (yes or no), diagnosis with
URTI (yes or no), diagnosis with tonsillitis (yes or no), diagnosis with bronchitis (yes or no), diagnosis season (cold and warm), provider specialty (general practice, family practice,
pediatrics, otolaryngology, other specialties), and IDPH intervention (before or after), and diagnosis year.
AOM, acute otitis media; IDPH, Iowa Department of Public Health; N/A, not available; URTI, upper respiratory tract infection.
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our theory suggests that this estimate is a lower bound
of the average effect of antibiotics for the treated
patients in our sample. In contrast, our IV-2SLS
models revealed no relationship between antibiotics
and cures for the set of “marginal” OM patients whose
treatment choices were affected by local area physician
supply. If, as we theorized, OM patients on the exten-
sive margin and the marginal OM patients within our
IV analysis are drawn from the set of patients for
whom the best treatment choice is least certain, our IV
results suggest that lowering the antibiotic treatment
rate for OM patients within the Iowa Medicaid popu-
lation during this time period would have not affected
the cure rate. As we suggested earlier, it is possible that
patients living in higher physician per capita areas
were healthier in general as a result of easier access to
health care. If true, our IV-2SLS estimates are biased
high and should be interpreted as upper-bound esti-
mates of the true effect of antibiotics for marginal OM
patients. Nevertheless, because no relationship was
found, this interpretation only reinforces the conclu-
sion that antibiotics had no beneﬁt for the marginal
patients whose treatment choices were affected by our
instrument. Because the beneﬁts of antibiotic treat-
ments are heterogeneous across OM patients, though,
policymakers should be cautious in using these results
to justify rate reduction from current rates without
additional analysis.
It should be noted that in our IV-2SLS models, the
overidentiﬁcation test was signiﬁcantly different from
zero when the instrument was speciﬁed using 20
patient groups. Overidentiﬁcation problems when a
large number of patient groups are speciﬁed has
occurred in other health-care studies using IV-2SLS
[31,33]. This result suggests there are limits in the
number of groups that can be speciﬁed using the
IV-2SLS approach without introducing spurious rela-
tionships between group membership and unmeasured
confounding variables.
This study demonstrates how the treatment varia-
tion within observational databases can provide useful
information for policymakers on treatment effective-
ness especially in cases in which treatment beneﬁts
are thought to be heterogeneous across patients. We
showed how theory can be used to bound estimates
and guide the application of alternative estimation
approaches such as risk-adjustment models and IV
approaches. Making inferences about patients on the
extensive margin requires a set of assumption regard-
less of the approach used. Ultimately, policymakers
should accumulate a variety of estimates and make
judgments based the strengths and limitations of each
estimation approach for the speciﬁc clinical setting.
Source of ﬁnancial support: This research was supported
through internal funds of the Health Effectiveness Research
Center (HERCe) at the University of Iowa.
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